Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,948 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Pneumonia Clear all
Not listed Phase 3 Interventional

Ravulizumab and COVID-19

NCT04570397
View directory record Official record
Conditions
Covid19, Thrombotic Microangiopathies, Acute Kidney Injury
Interventions
Ravulizumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 15, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

NCT04868890
View directory record Official record
Conditions
Covid19
Interventions
Ampion, Placebo
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

NCT04419623
View directory record Official record
Conditions
COVID-19, Sars-CoV2, Cancer, Solid Tumor, Carcinoma, Blood Cancer
Interventions
TL-895
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Augusta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 15, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

NCT04958889
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
Interventions
No intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 15, 2026, 5:10 AM EDT
Completed No phase listed Observational

Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops

NCT06163690
View directory record Official record
Conditions
Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Long Haul COVID, Long-Haul COVID-19
Interventions
Endourage Targeted Wellness Formula C™, a full hemp flower extract
Combination Product
Lead sponsor
Endourage, LLC
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

NCT04811339
View directory record Official record
Conditions
Diarrhea, COVID-19
Interventions
Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable, Placebo oral tablet without BSS
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

NCT04345653
View directory record Official record
Conditions
Covid19
Interventions
Hydroxychloroquine Sulfate (HCQ)
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 15, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Nudges to Improve Health Behaviors That Limit COVID-19 Spread

NCT04379375
View directory record Official record
Conditions
Health Behavior, COVID-19
Interventions
Nudge
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 15, 2026, 5:10 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

NCT04610801
View directory record Official record
Conditions
Covid19
Interventions
Nasal Spray
Drug
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 15, 2026, 5:10 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment for COVID-19 in High-Risk Adult Outpatients

NCT04354428
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
6
States / cities
Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

NCT04551911
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions
Rayaldee, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Sargramostim Use in COVID-19 to Recover Patient Health

NCT04707664
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Sargramostim, Placebo
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 15, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

NCT05438498
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Evusheld (tixagevimab+cilgavimab) IM or IV
Drug
Lead sponsor
MediMergent, LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
40
States / cities
Corona, California • Fountain Valley, California • Oxnard, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

NCT04625725
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
5,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Tempe, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 15, 2026, 5:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)

NCT05881135
View directory record Official record
Conditions
COVID-19
Interventions
Citicoline, Saline/Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 15, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

NCT04551378
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

NCT04780685
View directory record Official record
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 15, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Defibrotide for the Treatment of Severe COVID-19

NCT04652115
View directory record Official record
Conditions
Covid19
Interventions
Defibrotide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study

NCT04424004
View directory record Official record
Conditions
COVID 19
Interventions
COVID-19 PCR and serology testing
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 15, 2026, 5:10 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Study to Explore the Role of Gut Flora in COVID-19 Infection

NCT04359836
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, COVID, COVID-19, Corona Virus Infection, Coronavirus, Coronaviridae Infections, Coronavirus 19, Coronavirus-19, COVID 19
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 5:10 AM EDT
Completed No phase listed Observational

COVID-19 Antibody Levels After Vaccines

NCT04944134
View directory record Official record
Conditions
Vaccine Preventable Disease
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
71 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

NCT04785144
View directory record Official record
Conditions
COVID-19, COVID-19 Immunisation
Interventions
mRNA-1273, mRNA-1273.351
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 15, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trusted Messengers: Intervention to Promote COVID-19 Vaccination

NCT04981392
View directory record Official record
Conditions
Covid19, Vaccination
Interventions
Primary care text message outreach to unvaccinated patients and resources to support PCPs
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
21,844 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 15, 2026, 5:10 AM EDT